Related Experiment Video
Updated: May 2, 2026
11:36
In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones
Published on: July 25, 2019
10.6K
Stuck in the middle: drugging the ubiquitin system at the e2 step
J Wade Harper1, Randall W King
1Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA. wade_harper@hms.harvard.edu
Cell
|June 28, 2011
Summary
Researchers discovered a small-molecule inhibitor for the CDC34 ubiquitin-conjugating enzyme (E2). This finding suggests it may be possible to selectively block ubiquitin transfer, a key step in cellular processes.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- The ubiquitin-proteasome system regulates numerous cellular processes.
- CDC34 is a critical ubiquitin-conjugating enzyme (E2) involved in neddylation and DNA repair.
- Targeting E2 enzymes offers a potential strategy for therapeutic intervention.
Discussion:
- Ceccarelli et al. identified a novel small-molecule allosteric inhibitor of CDC34.
- Allosteric inhibition provides a mechanism for selective modulation of enzyme activity.
- This discovery opens avenues for developing specific inhibitors within the ubiquitin pathway.
Key Insights:
- A potent allosteric inhibitor of CDC34 has been discovered.
- Selective inhibition of ubiquitin transfer at the E2 level is demonstrated as feasible.
- This represents a significant advancement in targeting the ubiquitin pathway.
Outlook:
- Further investigation into the inhibitor's mechanism and therapeutic potential is warranted.
- This work could pave the way for new treatments targeting diseases associated with ubiquitin pathway dysregulation.
- Developing selective E2 inhibitors could offer precise control over cellular signaling and protein homeostasis.
Related Concept Videos
02:04Covalently Linked Protein Regulators
8.2K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
8.2K
02:18The Proteasome
7.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
7.8K
02:58Regulated Protein Degradation
6.6K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
6.6K
01:37The Unfolded Protein Response
5.6K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
5.6K
01:32Export of Misfolded Proteins out of the ER
4.3K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
4.3K
01:13The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K